GTC Biotherapeutics (fka GTCB)

[croumagnon]

GTCB is not exactly a developmental stage biotech. While it is not a source of revenues yet, it has already demonstrated its capability to manufacture transgenic bioequivalents and therefore you have to think of GTCB as a factory looking for product opportunities to manufacture.

ATryn is the first but many will likely follow. The anticipated initial revenues from the lauch of ATryn in the EU may be modest (about $25 Million per year) but nevertheless these revenues may be just enough to sustain the finances of GTCB for the foreseable future without necessitating another financing at these ridiculous price levels. That, in and by itself, is enough to minimize the risk in GTCB as opposed to a typical developmental stage biotech. The rest of the pipeline and partnership opportunities is what will make the stock price surge in due time. Consequently, I consider GTCB as an excellent risk/reward opportunity at the present time as the risk is truly minimal and the upside could be quite sizable...